



STATE MEDICAID P&T COMMITTEE MEETING
THURSDAY, May 20, 2010
7:00 a.m. to 8:30 a.m.
Cannon Health Building
Room 114



MINUTES

Committee Members Present:

Ellie Brownstein, M.D.
Michael Flynn, M.D.
Karen Gunning, PharmD.

Raymond Ward, M.D.
Duane Parke, R.Ph.
Brandon Jennings, PharmD.

Board Members Excused:

Beth Johnson, R.Ph.

Kort Delost, R.Ph.

Dept. of Health/Div. of Health Care Financing Staff Present:

Lisa Hulbert, R.Ph.
Jennifer Zeleny, CPhT, MPH

Tim Morley, R.Ph.
Richard Sorenson, RN

University of Utah Drug Information Center Staff Present:

Dave Peterson, PharmD.

Chris Beckwith, PharmD.

Other Individuals Present:

Denise Palatar, Teva	Robert Pearce, Teva	Scott Clegg, Lilly
Ed Hested, Teva	Julie Hubbard, EMD Serono	Rebecca Hirshier, Novo Nordisk
Brett Brewer, EMD Serono	Fran Gander, Novo Nordisk	Carrie Clark, Novo Nordisk
Mike Cuttender, Pfizer	Robe Meier, Pfizer	Lee Ding, Genentech
John Stockton, Genentech	Barry Hansen, Genentech	Ben Focht, Amylin
Alan Bailey, Pfizer	Sabrina Aery, BMS	David Donaldson, U of U
Nathan Spencer		

Meeting conducted by: Karen Gunning, PharmD, Co-Chairperson.

1. Minutes for April 2010 were reviewed, corrected, and approved. Dr. Ward moved to approve the minutes. Duane Parke seconded the motion. The motion was approved unanimously by Dr. Ward, Dr. Gunning, Dr. Brownstein, Dr. Jennings, and Duane Parke.

2. DUR Board Update: Lisa Hulbert addressed the Committee. The DUR Board did not meet in May 2010 due to lack of quorum. The Board also did not meet in April 2010 due to planned vacations. In June, the Board will be considering new PAs on tolvaptan and dronedarone. Recently, the DUR Board recommended a PA for Zovirax ointment to promote appropriate utilization.

3. Nicotine Replacement Therapy: Dr. Dave Peterson from the Drug

Information Service addressed the Committee and presented information on oral NRT that was compiled by the group.

Karen Gunning asked if there were any current controls on the nicotine replacement products. There are no quantity limits or prior authorization requirements for nicotine replacements.

The Committee clarified that only nicotine replacement products are being discussed for a PDL.

Dr. Flynn moved that the PRN medications are all equivalent, but that the PDL should include patches. Dr. Jennings seconded the motion. The motion was approved unanimously by Dr. Ward, Dr. Gunning, Dr. Brownstein, Dr. Jennings, Dr. Flynn and Duane Parke.

Duane Parke moved that all of the nicotine products are equally safe and efficacious. Dr. Brownstein seconded the motion. The motion was approved unanimously by Dr. Ward, Dr. Gunning, Dr. Brownstein, Dr. Jennings, Dr. Flynn and Duane Parke.

The Committee clarified that the PCN program and NTM program will not pay for any patches, and therefore cannot get NRT patches.

The Committee asked if Medicaid covers bupropion for smoking cessation. Tim stated that Medicaid requires that pharmacists classify bupropion as either smoking cessation or depression at the point of sale, but that the prescription would be covered regardless of diagnosis.

Karen Gunning suggested a DUR review to see if NRT products are being used appropriately, in terms of quantity and duration of therapy.

4. Growth Hormones: Dr. Christina Beckwith of the University of Utah Drug Information Services addressed the Committee and presented research prepared by the group.

Karen Gunning asked Rick what the current PA is for these agents. Rick stated that there are a number of criteria geared at linear growth problems for children, and AIDS wasting for adults. Even Prader-Willi criteria are based more on linear growth problems. The criteria do not distinguish whether or not a specialist versus general practitioner can prescribe it.

Duane Parke read a letter from Dr. James Grua, an endocrinologist and leading prescriber of growth hormone in Utah. The letter made a number of points stating that all of the products are essentially equal.

Dr. Frand Gander of Novo Nordisk addressed the Committee in favor of Norditropin and the Norditropin administration device.

Julie Hubbard of EMD Serono addressed the Committee in favor of Saizen and the Saizen delivery devices.

Dr. Lee Ding from Genentech addressed the Committee in favor of Nutropin and the Nutropin delivery devices.

Dr. Lori Blackner from Pfizer addressed the Committee in favor of Genotropin and Genotropin delivery devices.

Denice Palatas of Teva addressed the Committee in favor of Tevtropin and the Tevtropin delivery system.

The Committee stated that everyone in the room agrees that all versions of the drug are equally safe and efficacious, but that the question comes down to whether or not there are differences in the delivery devices. There is no evidence to support one or the other. However, having to draw up the vial could lead to patient error.

Dr. Ward felt that it was up to the physician to sort out whether or not a particular device would lead to noncompliance in a particular patient and decide whether or not to request a PA in those events.

Dr. Brownstein wondered about the differences in labeled indications. Dr. Ward did not find this to be a persuasive argument, as it was in other drug classes, because the molecule is identical in all of the growth hormone products.

Karen asked if there was a possibility to streamline a non-preferred authorization with the clinical PA. Jennifer gave an example of how this was handled for the anti-TNF class to keep it all as one clinical PA with an added bullet point for non-preferred products on the clinical PA.

Tim also stated that the letter from Dr. Grua minimized the need for dose accuracy for this particular drug. The dose needs to be achieved on a weekly versus daily basis. Karen indicated that her concern with dose accuracy with vials had as much to do with mixing errors as drawing it up. Duane added that the query he pulled on growth hormones did not indicate that wastage was a problem with any device.

Dr. Ward moved that there is no difference in safety and efficacy and that Medicaid select a product based on cost. He also moved that at least one product with a metered delivery device be included on the PDL. Ellie Brownstein seconded the motion. The motion was approved unanimously by Dr. Ward, Dr. Gunning, Dr. Brownstein, Dr. Jennings, Dr. Flynn and Duane Parke.

Duane Parke announced that this was his last P&T Committee meeting due to retirement.

Next Meeting Set for Thursday, July 15, 2010

There will be no meeting in June 2010

Meeting Adjourned.

Minutes prepared by Jennifer Zeleny